Negative Correlation between Neuregulin-4 and IL-9 Serum Levels in Patients with Coronary Artery Disease

(E-pub Ahead of Print)

Author(s): Hossein Farshidi, Nadereh Naderi, Hossein Montazerghaem, Narges Farshidi, Mahsa Rahimzadeh*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Become EABM
Become Reviewer
Call for Editor


Background: Neuregulin 4 (Nrg4) is a novel adipocytokine which has been proposed to play a role in modulating energy metabolism and pathogeneses of atherosclerosis. However, no published research is available about the mechanisms underlying the anti-atherosclerotic effect of Nrg4. Regarding the close link between adipocytokines and immune system, we wonder whether there is a relation between Nrg4 and athero-protective cytokines. The aim of this study was to investigate the relationship between serum Nrg4 levels and type 2 cytokines in Iranian patients with coronary artery disease (CAD).

Methods: In this case-control study, 125 CAD patients were compared to 55 healthy controls. Serum concentration of Nrg4, IL-5, IL-9 and IL-13 were measured using ELISA. The associations of circulating Nrg4 and IL-5, IL-9, IL-13 were assessed using linear regression analyses.

Results: Serum concentration of IL-9 was significantly higher in patients compared to the healthy controls (317.9±139 versus 228.3±99.1, P= ˂0.0001). IL-13 and Nrg4 were significantly lower in patients compared to the healthy controls (4.3±3.7 versus 6.1±3.9, P=0.01 and 0.5 versus 1.3, P=0.001 respectively). Multiple linear regression analyses revealed that IL-9 was negatively correlated with Nrg4 (β= -0.3, P=0.009).

Conclusion: Our study ،for the first-time, provides the clinical evidence revealing that circulating Nrg4 concentrations are inversely correlated with IL-9 in Iranian patients with CAD, suggesting that the protective role of Nrg4 on atherosclerosis may be, in part, mediated by the proatherogenic cytokine, IL-9.

Keywords: Coronary artery disease, IL-9, IL-5, IL-13, Neuregulin-4, case-control study.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871530321666210119115527
Price: $95

Article Metrics

PDF: 453